Cadrenal Therapeutics Inc. (NASDAQ: CVKD) announced plans to initiate a Phase 2a clinical trial of CAD-1005 for preventing acute kidney ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE